von Hentig N, Lötsch J
CYP3A inhibition by atazanavir and ritonavir, but not demography or drug formulation, influences saquinavir population pharmacokinetics in HIV-1 infected adults. [JOURNAL ARTICLE]
Antimicrob Agents Chemother 2009 Jun 15.
Inadequate concentrations of the HIV protease inhibitor saquinavir jeopardize the individual therapy success or produce side effects despite treatment according to the current guidelines. We performed a population pharmacokinetic analysis with NONMEM and indentified that steady-state saquinavir pharmacokinetics in 136 HIV-1 infected adults were modulated by a decrease in saquinavir clearance following co-administration of CYP3A inhibitors ritonavir and atazanavir. In contrast, age, sex, weight, pregnancy or the pharmaceutical formulation exerted only minor non-significant effects.
More from this journal |
